SGLT2 Inhibitors and Cardiovascular Outcomes

Current Perspectives and Future Potentials

Xiaoming Jia, Paras B. Mehta, Yumei Ye, Mahboob Alam, Yochai Birnbaum, Mandeep Bajaj

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Purpose of Review: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to exert benefit on cardiac outcomes. In this review, we provide updates on available clinical data, studies on potential mechanisms for the CV effects, as well as discuss potential clinical implications of these new findings. Recent Findings: Since the publications of the EMPA-REG and CANVAS trials, large multi-national cohort studies have further shown the cardioprotective effects of SGLT2i. Moreover, new studies examining SGLT2i action on sodium-hydrogen exchanger proteins in both the heart and the kidney, on myocardial energetics and impact on inflammation and atherosclerosis continue to shed light on the multitude of pleotropic effects of these agents. Summary: Though more data is needed to substantiate the safety and efficacy, SGLT2i should be considered as a valuable therapy to help reduce CV risk in patients with diabetes. Ultimately, SGLT2i may have utility in preventing progression to diabetes or providing CV protection in patients who do not have diabetes.

Original languageEnglish (US)
Article number63
JournalCurrent Diabetes Reports
Volume18
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Sodium-Glucose Transport Proteins
Sodium-Hydrogen Antiporter
Publications
Atherosclerosis
Cohort Studies
Inflammation
Kidney
Safety
Proteins

Keywords

  • Cardiovascular outcomes
  • SGLT2 inhibitor
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

SGLT2 Inhibitors and Cardiovascular Outcomes : Current Perspectives and Future Potentials. / Jia, Xiaoming; Mehta, Paras B.; Ye, Yumei; Alam, Mahboob; Birnbaum, Yochai; Bajaj, Mandeep.

In: Current Diabetes Reports, Vol. 18, No. 9, 63, 01.09.2018.

Research output: Contribution to journalReview article

Jia, Xiaoming ; Mehta, Paras B. ; Ye, Yumei ; Alam, Mahboob ; Birnbaum, Yochai ; Bajaj, Mandeep. / SGLT2 Inhibitors and Cardiovascular Outcomes : Current Perspectives and Future Potentials. In: Current Diabetes Reports. 2018 ; Vol. 18, No. 9.
@article{e34ed3384ba14219b41a935f79008af9,
title = "SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials",
abstract = "Purpose of Review: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to exert benefit on cardiac outcomes. In this review, we provide updates on available clinical data, studies on potential mechanisms for the CV effects, as well as discuss potential clinical implications of these new findings. Recent Findings: Since the publications of the EMPA-REG and CANVAS trials, large multi-national cohort studies have further shown the cardioprotective effects of SGLT2i. Moreover, new studies examining SGLT2i action on sodium-hydrogen exchanger proteins in both the heart and the kidney, on myocardial energetics and impact on inflammation and atherosclerosis continue to shed light on the multitude of pleotropic effects of these agents. Summary: Though more data is needed to substantiate the safety and efficacy, SGLT2i should be considered as a valuable therapy to help reduce CV risk in patients with diabetes. Ultimately, SGLT2i may have utility in preventing progression to diabetes or providing CV protection in patients who do not have diabetes.",
keywords = "Cardiovascular outcomes, SGLT2 inhibitor, Type 2 diabetes",
author = "Xiaoming Jia and Mehta, {Paras B.} and Yumei Ye and Mahboob Alam and Yochai Birnbaum and Mandeep Bajaj",
year = "2018",
month = "9",
day = "1",
doi = "10.1007/s11892-018-1038-9",
language = "English (US)",
volume = "18",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "9",

}

TY - JOUR

T1 - SGLT2 Inhibitors and Cardiovascular Outcomes

T2 - Current Perspectives and Future Potentials

AU - Jia, Xiaoming

AU - Mehta, Paras B.

AU - Ye, Yumei

AU - Alam, Mahboob

AU - Birnbaum, Yochai

AU - Bajaj, Mandeep

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Purpose of Review: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to exert benefit on cardiac outcomes. In this review, we provide updates on available clinical data, studies on potential mechanisms for the CV effects, as well as discuss potential clinical implications of these new findings. Recent Findings: Since the publications of the EMPA-REG and CANVAS trials, large multi-national cohort studies have further shown the cardioprotective effects of SGLT2i. Moreover, new studies examining SGLT2i action on sodium-hydrogen exchanger proteins in both the heart and the kidney, on myocardial energetics and impact on inflammation and atherosclerosis continue to shed light on the multitude of pleotropic effects of these agents. Summary: Though more data is needed to substantiate the safety and efficacy, SGLT2i should be considered as a valuable therapy to help reduce CV risk in patients with diabetes. Ultimately, SGLT2i may have utility in preventing progression to diabetes or providing CV protection in patients who do not have diabetes.

AB - Purpose of Review: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to exert benefit on cardiac outcomes. In this review, we provide updates on available clinical data, studies on potential mechanisms for the CV effects, as well as discuss potential clinical implications of these new findings. Recent Findings: Since the publications of the EMPA-REG and CANVAS trials, large multi-national cohort studies have further shown the cardioprotective effects of SGLT2i. Moreover, new studies examining SGLT2i action on sodium-hydrogen exchanger proteins in both the heart and the kidney, on myocardial energetics and impact on inflammation and atherosclerosis continue to shed light on the multitude of pleotropic effects of these agents. Summary: Though more data is needed to substantiate the safety and efficacy, SGLT2i should be considered as a valuable therapy to help reduce CV risk in patients with diabetes. Ultimately, SGLT2i may have utility in preventing progression to diabetes or providing CV protection in patients who do not have diabetes.

KW - Cardiovascular outcomes

KW - SGLT2 inhibitor

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85049828995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049828995&partnerID=8YFLogxK

U2 - 10.1007/s11892-018-1038-9

DO - 10.1007/s11892-018-1038-9

M3 - Review article

VL - 18

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 9

M1 - 63

ER -